The FDA has approved a new drug called zolbetuximab designed to attack a novel target that’s in a type of stomach cancer.
Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy ...
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
A new study published in the Journal of Clinical Tuberculosis and Other Mycobacterial Diseases showed that two ...
On September 10, experts across disciplines, from infectious disease clinicians to regulators to representatives from the pharmaceutical industry, convened at the inaugural ImmunOptimize workshop in ...
With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...
The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...
High rates of virologic suppression were observed among Black patients who received long-term ART with BIC/FTC/TAF for HIV management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback